Definium Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026The company got cash to develop its depression drug DT120 and cover business costs.
Official document giving investors complete information about how the stock offering works.
Official document giving investors complete information about how the stock offering works.
Successful test results make the drug more likely to get approved and help patients.
Company can now give more stock rewards to employees to attract and keep talent.
Gives investors current information about the company's progress and plans.
Testing of the drug moved forward, bringing it closer to possible approval.
Stocky reads Definium Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Definium Therapeutics, Inc.'s most recent tracked filing was a 8-K on 24 Jun 2026: Raises $758 million through stock offering at $34 per share.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.